PC
JAZZ icon

Parrish Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parrish Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$652K Buy
3,448
+407
+13% +$71.1K 0.58% 69
2025
Q4 		$517K Buy
+3,041
New +$466K 0.47% 74

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Parrish Capital's JAZZ Position: Q1 2026 in Review

Parrish Capital increased its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q1 2026, buying an estimated $71.1K and bringing the position to 3,448 shares worth $652K. The position accounts for 0.58% of the portfolio, ranked #69.

Parrish Capital first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Parrish Capital held 3,448 shares of Jazz Pharmaceuticals worth $652K as of Q1 2026.
  • Parrish Capital bought 407 Jazz Pharmaceuticals shares in Q1 2026, an estimated $71.1K.
  • Jazz Pharmaceuticals made up 0.58% of Parrish Capital's portfolio in Q1 2026, its #69 holding.
  • Parrish Capital first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Parrish Capital's 13F filing for Q1 2026, filed 28 Apr 2026.